Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4.

[1]  Y. Higashimoto,et al.  RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy , 2017, Diabetes.

[2]  R. Gilbert.  Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease , 2017, Diabetes.

[3]  S. Yamagishi,et al.  Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis , 2015, Laboratory Investigation.

[4]  S. Yamagishi,et al.  Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications , 2015, Cardiovascular Diabetology.

[5]  T. Sécher,et al.  Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy , 2014, Journal of hypertension.

[6]  A. Avogaro,et al.  The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications , 2014, Diabetes Care.

[7]  S. Yamagishi,et al.  Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis , 2014, Hormone and Metabolic Research.

[8]  P. Veronesi,et al.  Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells , 2014, Experimental biology and medicine.

[9]  Y. Higashimoto,et al.  Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor , 2013, Cardiovascular Diabetology.

[10]  T. Imaizumi,et al.  Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. , 2013, Clinical biochemistry.

[11]  R. Ramasamy,et al.  The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. , 2012, Vascular pharmacology.

[12]  S. Yamagishi,et al.  Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. , 2011, Current pharmaceutical design.

[13]  S. Yamagishi,et al.  Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. , 2011, Pharmacological research.

[14]  M. Cooper,et al.  Glycation in diabetic nephropathy , 2012, Amino Acids.

[15]  S. Yamagishi,et al.  Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. , 2010, Microvascular research.

[16]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[17]  P. Vinay,et al.  Isolation of a pure suspension of rat proximal tubules. , 1981, The American journal of physiology.